Overview：Non-ATP Competitive CDC7 Inhibitor for Treatment of Broad Variety of Cancer Types
LBS-007 is a novel targeted therapy for the treatment of a broad array of cancers. It has demonstrated activity against leukemia and solid tumors, especially in chemotherapy-resistant cell lines and other cancer cell lines.
LBS-007 has obtained Orphan Drug Destination (ODD) for Acute Lymphoma Leukemia (ALL) from US FDA in 2018/March and is expected to enter a first-in-human Phase 1 trial in 2022.
Leukemias are a group of blood cancers (liquid cancers) that are characterized by abnormal white blood cells (leukocytes). Multiple types of leukemia exists, impacting both children and adults. The most common types of leukemia are acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). Leukemia treatments often include a combination of chemotherapy, radiation and bone marrow transplantation. The survival rates for leukemia vary depending on the type. For example, under the current standards of care, the overall five-year survival rate for leukemias is approximately 60% : in contrast, it’s only 25% in adults with ALL and AML.
Pancreatic cancer is one of the most deadly of all types of cancer. Current treatment options are limited and according to the American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 7%.
Most women with ovarian cancer are diagnosed with advanced-stage disease. Stage IV ovarian cancer have a five-year survival rate of approximately 17%. Current treatment options are limited and ovarian cancer remains one of the most difficult cancers to treat.
How it Works (Mechanism of Action)：Disrupting Cancer Cell Cycles
In order to spread, a tumor cell grows, duplicates its DNA and then divides, resulting in two cancer tumor cells. The process of cancer cell growth and division is marked by several phases within the cell (division) cycle. During the S phase of the cycle, a cancer cell duplicates its DNA, which contains the genetic information required for survival.
LBS-007 inhibits cancer cell replication by interrupting the S phase of the cell cycle. Its mechanism of action is to inhibit a key regulator protein of the cell cycle, CDC7. Inhibition of CDC7 stops the proliferation of tumor cells and results in cancer cell death. Because CDC7’s activity is often upregulated in cancer cells in comparison to healthy cells, it’s an ideal candidate for a targeted anti-cancer therapy.